The Oncology Institute, Inc. (STLN) — Strategic Asset Allocation Index
The Oncology Institute, Inc. (STLN) has a Strategic Asset Allocation Index of 0.0% as of December 2023. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $57.02 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check The Oncology Institute, Inc. (STLN) tangible equity ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
The Oncology Institute, Inc. Strategic Asset Allocation Index (2022–2023)
This chart shows how The Oncology Institute, Inc.'s Strategic Asset Allocation Index has evolved across 2 annual periods from 2022 to 2023. As of December 2023, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $57.02 Million USD.
Annual Strategic Asset Allocation Index for The Oncology Institute, Inc. (2022–2023)
The table below presents the year-by-year Strategic Asset Allocation Index for The Oncology Institute, Inc. from 2022 to 2023, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see The Oncology Institute, Inc. (STLN) total market value.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 0.0% | $0.00 | $- | $0.00 | $57.02 Million | ▼ -47.4 pp |
| 2022 | 47.4% | $58.35 Million | $- | $58.35 Million | $123.17 Million | — |